Wolfe Research Starts CRISPR Therapeutics (CRSP) at Peerperform
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $53.99 --0%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 9
Join SI Premium – FREE
Wolfe Research analyst Andy Chen initiates coverage on CRISPR Therapeutics (NASDAQ: CRSP) with a Peerperform rating.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $72.78 yesterday.
You May Also Be Interested In
- Lake Street Starts RF Industries Ltd. (RFIL) at Buy
- Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
- JPMorgan Starts SITC International Holdings Co Ltd (1308:HK) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
